1. bookVolume 72 (2022): Issue 2 (June 2022)
Journal Details
License
Format
Journal
eISSN
1846-9558
First Published
28 Feb 2007
Publication timeframe
4 times per year
Languages
English
access type Open Access

Anti-inflammatory and immunomodulatory effects of rosuvastatin in patients with low-to-moderate cardiovascular risk

Published Online: 30 Dec 2021
Page range: 303 - 315
Accepted: 21 Jun 2021
Journal Details
License
Format
Journal
eISSN
1846-9558
First Published
28 Feb 2007
Publication timeframe
4 times per year
Languages
English
Abstract

Statins have shown anti-inflammatory pleiotropic effects in subjects with/at risk of cardiovascular disease. The aim of this study was to evaluate the inflammatory/immunomodulatory properties of rosuvastatin in subjects at low-to-moderate cardiovascular risk. Data was collected from patients’ records, physical examination and blood sampling. Subjects were assigned to rosuvastatin 20 mg per day. Rosuvastatin significantly decreased C-reactive protein (p = 0.045), and increased vascular endothelial growth factor (p = 0.004) and epidermal growth factor (p = 0.009). A multivariate analysis identified total cholesterol (p = 0.027) and vascular endothelial growth factor (p = 0.011) to be independently associated with rosuvastatin treatment. Given beneficial/harmful role of growth factors, vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF), in cardiovascular disease, one would suggest the need for routine monitoring of growth factor levels, especially in patients on long-term statin therapy.

Keywords

M. F. Piepoli, A. W. Hoes, S. Agewall, C. Albus, C. Brotons, A. L. Catapano, M. Cooney, U. Corrà, B. Cosyns, C. Deaton, I. Graham, M. S. Hall, F. D. R. Hobbs, M. Løchen, H. Löllgen, P. Marques-Vidal, J. Perk, E. Prescott, J. Redon, D. J. Richter, N. Sattar, Y. Smulders, M. Tiberi, H. B. van der Worp, I. van Dis, W. M. M. Verschuren and S. Binno, 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The sixth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR), Eur. Heart J. 37 (2016) 2315–2381; https://doi.org/10.1093/eurheartj/ehw10610.1093/eurheartj/ehw106Search in Google Scholar

J. L. Fleg, G. W. Stone, Z. A. Fayad, J. F. Granada, T. S. Hatsukami, F. D. Kolodgie, J. Ohayon, R. Pettigrew, M. S. Sabatine, G. J. Tearney, S. Waxman, M. J. Domanski, P. R. Srinivas and J. Narula, Detection of high-risk atherosclerotic plaque: report of the NHLBI working group on current status and future directions, JACC Cardiovasc. Imag. 5 (2012) 941–955; https://doi.org/10.1016/j.jcmg.2012.07.00710.1016/j.jcmg.2012.07.007Search in Google Scholar

P. Libby, P. M. Ridker and G. K. Hansson, Inflammation in atherosclerosis: From pathophysiology to practice, J. Am. Coll. Cardiol. 54 (2009) 2129–2138; https://doi.org/10.1016/j.jacc.2009.09.00910.1016/j.jacc.2009.09.009Search in Google Scholar

L. H. Kuller, R. P. Tracy, J. Shaten and E. N. Meilahn, Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple risk factor intervention trial, Am. J. Epidemiol. 144 (1996) 537–547; https://doi.org/10.1093/oxfordjournals.aje.a00896310.1093/oxfordjournals.aje.a008963Search in Google Scholar

P. M. Ridker, N. Rifai, L. Rose, J. E. Buring and N. R. Cook, Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events, N. Engl. J. Med. 347 (2002) 1557–1565; https://doi.org/10.1056/NEJMoa02199310.1056/NEJMoa021993Search in Google Scholar

S. Kaptoge, E. Di Angelantonio, G. Lowe, M. B. Pepys, S. G. Thompson, R. Collins and J. Danesht, C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis, Lancet 375 (2010) 132–140; https://doi.org/10.1016/S0140-6736(09)61717-710.1016/S0140-6736(09)61717-7Search in Google Scholar

V. Lubrano and S. Balzan, Consolidated and emerging inflammatory markers in coronary artery disease, World J. Exp. Med. 5 (2015) 21–32; https://doi.org/10.5493/wjem.v5.i1.2110.5493/wjem.v5.i1.21Search in Google Scholar

I. Subirana, M. Fitó, O. Diaz, J. Vila, A. Francés, E. Delpon, J. Sanchis, R. Elosua, D. Muñoz-Aguayo, I. R. Dégano and J. Marrugat, Prediction of coronary disease incidence by biomarkers of inflammation, oxidation, and metabolism, Sci. Rep. 8 (2018) Article ID 3191; https://doi.org/10.1038/s41598-018-21482-y10.1038/s41598-018-21482-ySearch in Google Scholar

E. Diamantis, G. Kyriakos, L. V. Quiles-Sanchez, P. Farmaki and T. Troupis, The anti-inflammatory effects of statins on coronary artery disease: An updated review of the literature, Curr. Cardiol. Rev. 13 (2017) 209–216; https://doi.org/10.2174/1573403X1366617042610461110.2174/1573403X13666170426104611Search in Google Scholar

F. Mach, C. Baigent, A. L. Catapano, K. C. Koskinas, M. Casula, L. Badimon, M. J. Chapman, G. G. De Backer, V. Delgado, B. A. Ference, I. M. Graham, A. Halliday, U. Landmesser, B. Mihaylova, T. R. Pedersen, G. Riccardi, D. J. Richter, M. S. Sabatine, M. Taskinen, L. Tokgozoglu and O. Wiklund, 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS), Eur. Heart J. 41 (2020) 111–188; https://doi.org/10.1093/eurheartj/ehz45510.1093/eurheartj/ehz455Search in Google Scholar

D. Tousoulis, C. Psarros, M. Demosthenous, R. Patel, C. Antoniades and C. Stefanadis, Innate and adaptive inflammation as a therapeutic target in vascular disease: the emerging role of statins, J. Am. Coll. Cardiol. 63 (2014) 2491–2502; https://doi.org/10.1016/j.jacc.2014.01.05410.1016/j.jacc.2014.01.054Search in Google Scholar

C. Demir, C. Anil, Y. Bozkus, U. Mousa, A. Kut, A. Nar and N. B. Tutuncu, Do statins affect thyroid volume and nodule size in patients with hyperlipidemia in a region with mild-to-moderate iodine deficiency? A Prospective Study, Med. Princ. Pract. 27 (2018) 1–7; https://doi.org/10.1159/00048674810.1159/000486748Search in Google Scholar

M. L. Muiesan, C. Agabiti-Rosei, A. Paini and M. Salvetti, Uric acid and cardiovascular disease: An update, Eur. Cardiol. 11 (2016) 54–59; https://doi.org/10.15420/ecr.2016:4:210.15420/ecr.2016:4:2Search in Google Scholar

G. Derosa, P. Maffioli, Ž. Reiner, L. E. Simental-Mendía and A. Sahebkar, Impact of statin therapy on plasma uric acid concentrations: A systematic review and meta-analysis, Drugs 76 (2016) 947–956; https://doi.org/10.1007/s40265-016-0591-210.1007/s40265-016-0591-2Search in Google Scholar

D. Ferro, S. Parrotto, S. Basili, C. Alessandri and F. Violi, Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia, J. Am. Coll. Cardiol. 36 (2000) 427–431; https://doi.org/10.1016/S0735-1097(00)00771-310.1016/S0735-1097(00)00771-3Search in Google Scholar

E. Mandosi, M. Fallarino, A. Gatti, A. Carnovale, M. Rossetti, E. Lococo, B. Buchetti, S. Filetti, L. Lenti and S. Morano, Atorvastatin downregulates monocyte CD36 expression, nuclear NFkB and TNF-a levels in type 2 diabetes, J. Atheroscler. Thromb. 17 (2010) 539–545; https://doi.org/10.5551/jat.295610.5551/jat.2956Search in Google Scholar

T. Lyngdoh, P. Vollenweider, G. Waeber and P. M. Vidal, Association of statins with inflammatory cytokines: a population based Colaus study, Atherosclerosis 219 (2011) 253–258; https://doi.org/10.1016/j.atherosclerosis.2011.07.11710.1016/j.atherosclerosis.2011.07.117Search in Google Scholar

P. Karmaus, M. Shi, S. Perl, A. Biancotto, J. Candia, F. Cheung, Y. Kotliarov, N. Young and M. B. Fessler, Effects of rosuvastatin on the immune system in healthy volunteers with normal serum cholesterol, JCI Insight 4 (2019) e131530; https://doi.org/10.1172/jci.insight.13153010.1172/jci.insight.131530Search in Google Scholar

I. Karu, J. Starkopf, K. Zilmer and M. Zilmer, Growth factors serum levels in coronary artery disease patients scheduled for bypass surgery: Perioperative dynamics and comparisons with healthy volunteers, BioMed Res. Int. 2013 (2013) Article ID 985404; https://doi.org/10.1155/2013/98540410.1155/2013/985404Search in Google Scholar

C. Camaré, M. Pucelle, A. Nègre-Salvayre and R. Salvayre, Angiogenesis in the atherosclerotic plaque, Redox Biol. 12 (2017) 18–34; https://doi.org/10.1016/j.redox.2017.01.00710.1016/j.redox.2017.01.007Search in Google Scholar

J. Dulak and A. Józkowicz, Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti--cancer therapy, Curr. Cancer Drug Targets 5 (2005) 579–594; https://doi.org/10.2174/15680090577493282410.2174/156800905774932824Search in Google Scholar

M. Weis, C. Heeschen, A. J. Glassford and J. P. Cooke, Statins have biphasic effects on angiogenesis, Circulation 105 (2002) 739–745; https://doi.org/10.1161/hc0602.10339310.1161/hc0602.103393Search in Google Scholar

A. Giurgea, C. Margeta, T. Maca, A. Rezaie-Majd, R. A. Bucek, M. Manavi, R. Afarideh, E. Minar and M. Baghestanian, Simvastatin reduces serum level of vascular endothelial growth factor in hypercholesterolemic patients, J. Cardiovasc. Pharmacol. 47 (2006) 30–36; https://doi.org/10.1097/01.fjc.0000191970.65998.7a10.1097/01.fjc.0000191970.65998.7aSearch in Google Scholar

H. F. Alber, J. Dulak, M. Frick, W. Dicht, S. P. Schwarzacher, O. Pachinger and F. Weidinger, Atorvastatin decreases vascular endothelial growth factor in patients with coronary artery disease, J. Am. Coll. Cardiol. 39 (2002) 1951–1955; https://doi.org/10.1016/S0735-1097(02)01884-310.1016/S0735-1097(02)01884-3Search in Google Scholar

V. Capra and G. E. Rovati, Rosuvastatin inhibits human airway smooth muscle cells mitogenic response to eicosanoid contractile agents, Pulm. Pharmacol. Ther. 27 (2014) 10–16; https://doi.org/10.1016/j.pupt.2013.06.00510.1016/j.pupt.2013.06.005Search in Google Scholar

K. Yokohama, S. Fukunishi, M. Ii, K. Nakamura, H. Ohama, Y. Tsuchimoto A. Asai, Y. Tsuda and K. Higuchi, Rosuvastatin as a potential preventive drug for the development of hepatocellular carcinoma associated with non-alcoholic fatty liver disease in mice, Int. J. Mol. Med. 38 (2016) 1499–1506; https://doi.org/10.3892/ijmm.2016.276610.3892/ijmm.2016.2766Search in Google Scholar

S. Cantoni, C. Cavallini, F. Bianchi, F. Bonavita, V. Vaccari, E. Olivi, I. Frascari, R. Tassinari, S. Valente, V. Lionetti and C. Ventura, Rosuvastatin elicits KDR-dependent vasculogenic response of human placental stem cells through PI3K/AKT pathway, Pharmacol. Res. 65 (2012) 275–284; https://doi.org/10.1016/j.phrs.2011.12.00410.1016/j.phrs.2011.12.004Search in Google Scholar

V. G. Chantzichristos, A. P. Agouridis, E. Moutzouri, K. Stellos, M. S. Elisaf and A. D. Tselepis, Plasma VEGF and IL-8 levels in patients with mixed dyslipidaemia. Effect of rosuvastatin monotherapy or its combination at a lower dose with omega-3 fatty acids: A pilot study, Curr. Vasc. Pharmacol. 14 (2016) 474–480; https://doi.org/10.2174/157016111466616040412534110.2174/1570161114666160404125341Search in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo